Literature DB >> 19075944

Recent patents relating to siRNAs and therapeutic strategies for genetic diseases.

Daniel Grinberg1.   

Abstract

RNA interference has been implicated in diverse biological process. It is a powerful method for specific gene silencing which may also lead to promising novel therapeutic strategies. The success of early studies of therapeutic RNAi in rodent models has generated considerable interest on the development of RNAi as a potential therapy. A number of recent patents have been published that deal with the use of siRNA as therapeutic tools for human diseases. In this review, I will comment on some of the patents issued on siRNA-based strategies for cancer, ocular diseases, cardiovascular disease, Alzheimer's disease, Parkinson's disease, bone healing, and monogenic diseases such as amyotrophic lateral sclerosis, Marfan syndrome or Huntingon's disease. Progress in developing RNAi-based drugs and potential obstacles will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075944     DOI: 10.2174/187221508783406530

Source DB:  PubMed          Journal:  Recent Pat DNA Gene Seq        ISSN: 1872-2156


  2 in total

1.  A laboratory-intensive course on RNA interference and model organisms.

Authors:  Joanna A Miller; D Scott Witherow; Susan Carson
Journal:  CBE Life Sci Educ       Date:  2009       Impact factor: 3.325

2.  Inhibition of ATIR by shRNA prevents collagen synthesis in hepatic stellate cells.

Authors:  Peihong Dong; Fujun Yu; Xufei Fan; Zhuo Lin; Yongping Chen; Ji Li
Journal:  Mol Cell Biochem       Date:  2010-08-12       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.